The global small animal imaging (In-Vivo) market was valued at US$ 1,053 million in 2023.
The global small animal imaging (In-Vivo) market was valued at US$ 1,053 million in 2023. The global market is projected to hit a valuation of US$ 1,902 million by 2032 at a CAGR of 6.79% during the forecast period from 2024 to 2032.
The global small animal imaging (in-vivo) market is experiencing rapid growth. The increasing need for preclinical research in drug development and disease modeling is driving market growth. For instance, regulatory bodies like the FDA have been increasingly granting approvals for new medications. In 2022, the FDA gave the green light to 55 new drugs, the highest number of approvals in more than twenty years. Small-animal imaging is a crucial tool in early-stage research throughout the industry as developers strive to comprehend the cellular-level mechanisms of drug action prior to human testing. Furthermore, the market growth is due to the expanding applications of small animal imaging in emerging research fields such as regenerative medicine and gene therapy.
Get report sample pages@ https://www.astuteanalytica.com/request-sample/small-animal-imaging-in-vivo-market
The future of the small animal imaging (in-vivo) market is indeed looking bright, with a growing demand for preclinical research, especially in drug development and disease modeling. Whole-body imaging of small animals is a sophisticated and cost-efficient method. This serves as an experimental platform for the timely validation and commercialization of new agents from the laboratory to practical use. This technology is attractive to pharmaceutical developers due to its unique benefits, including the capacity to monitor cells and molecules, observe metabolic processes using radiolabeled tracers, provide high-quality 3D imaging of internal structures, and deliver exceptional soft-tissue contrast.
Small animal imaging plays a crucial role in understanding the underlying mechanisms of conditions such as cancer, diabetes, cardiovascular, immunological, and neurodegenerative diseases. According to the analysis by Astute Analytica, the cancer cell detection segment is set for significant expansion, boasting the highest CAGR of 7.83% over the projected period. The prominence of bio-distribution and drug/target engagement studies can be credited to their crucial involvement in the drug development process. These functions offer vital understandings of the interactions between drugs and the body, influencing decisions in both preclinical and clinical stages.
Technological Advancement: Enhancing the Capabilities of Imaging System
Technological advancements have significantly enhanced the capabilities of imaging systems, leading to improvements in the quality and efficiency of preclinical imaging studies. Advancements in imaging systems, including multimodal imaging systems, high-resolution imaging, and the adoption of artificial intelligence, have significantly improved the quality and efficiency of preclinical imaging studies, which offer lucrative opportunities for the small animal imaging (in-vivo) market.
- High-Resolution Imaging: Innovations in high-resolution imaging have allowed for the capture of detailed biological changes over time at a molecular level, enabling researchers to track subtle details.
- Multimodal Imaging Systems: The integration of multimodal imaging systems, such as PET/CT or MRI/Optical Imaging hybrid systems, has gained popularity in the market. These systems enable multiple screening in a single unit and are likely to boost the growth of the multi-modal imaging devices market in preclinical studies.
- Integration of Artificial Intelligence: The integration of artificial intelligence for image analysis has further improved the quality and efficiency of preclinical imaging studies. This has led to the development of AI-powered tools that enhance image analysis, aiding in the detection, characterization, and treatment planning of complex diseases.
- Growth of Novel Imaging Reagents and Probes: With the development of probes and reagents that target specific biological processes, studies have become more precise and comprehensive.
Optical Imaging Systems: Dominating the Small Animal Imaging (In-Vivo) Market
In the in-vivo small animal imaging market, optical imaging systems are gaining significant momentum due to their bioluminescence (BLI) and fluorescence (FLI) properties, which own a 25.4% revenue stake of the global market, contributing over US$267.46 million in 2023 alone.
The use of optical-imaging-based technology in drug development allows for real-time observations of new drug candidates within living organisms. This enables researchers to test new drugs more quickly and with more accurate data, ultimately leading to better results from pharmaceutical companies in the small animal imaging (in-vivo) market.
Furthermore, scientists can observe the growth of cancer or other serious illnesses in non-human subjects by using fluorescent or bioluminescent reporters. This information is then used when developing new therapies that can help cure these illnesses.
Pairing optical imaging with PET and MRI scans can provide an extremely thorough understanding of how these systems work and react together. This integration is essential in furthering our knowledge of disease dynamics, which can lead to the development of personalized medicine catering to each specific patient’s needs. Companies like PerkinElmer, Bruker, and LI-COR Biosciences provide some of these systems, but there are other competitors in this crowded field.
Ask here for customization study@ https://www.astuteanalytica.com/ask-for-customization/small-animal-imaging-in-vivo-market
North America Takes the Lead in the Global Small Animal Imaging (in-vivo) Market
North America dominated the global small animal imaging (in-vivo) market in 2023, holding a substantial market share of more than 43.5%. The United States played a significant role in this regional dominance, being the leading contributor.
The US has some of the best research institutions, thanks to generous government and private funding in life sciences research. This has led to a lot of innovation and demand for advanced preclinical imaging technology. For instance, The US government has allocated a significant investment in the National Institutes of Health (NIH), amounting to nearly $48.6 billion. This substantial funding is primarily directed towards medical research for the American people, with approximately 83% of the NIH’s budget being awarded for extramural research through competitive grants to researchers at various institutions across the country.
Another driving factor is the high healthcare spending in the US, which fuels the demand for sophisticated imaging systems, particularly in the biotech industry where small animal imaging plays a crucial role in expediting drug development pipelines. For instance, in 2022, the United States allocated $4.5 trillion for healthcare, which accounted for 17.3% of the nation’s Gross Domestic Product (GDP).
The large volume of clinical trials and drug approvals in North America further boosts the demand for small animal imaging systems, particularly in the preclinical stages to ensure drug safety before human testing. For instance, in 2022, the FDA approved 37 novel drugs, which was the fewest to pass regulatory scrutiny since 2016. However, in 2023, there were over 47,000 active clinical trials, indicating a significant level of ongoing research and development in the pharmaceutical industry.
With continued funding, advancements in personalized medicine, and ongoing developments in advanced imaging systems, North America’s dominance in the global small animal imaging (in-vivo) market is expected to persist.
Global Small Animal Imaging (In-Vivo) Market Players
- Bruker Corporation
- Siemens A.G
- Agilent Technologies
- Fujifilm Corporation
- Hologic, Inc.
- Mediso Ltd.
- TriFoil Imaging
- PerkinElmer
- MILabs B.V.
- MR Solutions
- Thermo Fisher Scientific
- Other Major Players
Market Segmentation Overview
By Modality
- CT Imaging
- MRI System
- Nuclear Imaging System
- Optical Imaging System
- Ultrasound Imaging
- Photoacoustic Imaging
- Magnetic Particle Imaging (MPI)
By Application
- Monitoring treatment response
- Bio-distribution, determining drug/target engagement
- Cancer cell detection
- Biomarkers
- Epigenetics
- Other
By End Use
- Biotech Companies
- Pharmaceutical companies
- Research institutes
By Region
- North America
- Europe
- Asia Pacific
- Middle East & Africa (MEA)
- South America
Get full access of this report@ https://www.astuteanalytica.com/industry-report/small-animal-imaging-in-vivo-market?buy_now=true&license_type=single
Contact us:
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
Email: sales@astuteanalytica.com
Website: https://www.astuteanalytica.com/